查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1668103

骨髓增生异常综合症治疗市场 - 全球行业规模、份额、趋势、机会和预测，按治疗类型、按最终用户、按地区和竞争细分，2020-2030 年预测

Myelodysplastic Syndrome Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Treatment Type, By End User, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2024 年全球骨髓增生异常症候群 (MDS) 治疗市场价值为 29.5 亿美元，预计到 2030 年将达到 42 亿美元，预测期内复合年增长率为 6.02%。骨髓增生异常综合症 (MDS) 是一组以骨髓血球生成功能障碍为特征的血液疾病。它会影响红血球、白血球和血小板的生成，导致各种症状和併发症。多年来，MDS 的诊断和治疗取得了重大进展，导致全球 MDS 治疗市场不断成长。 MDS 主要影响老年人，但它可能发生在任何年龄。它通常被认为是白血病前期病症，因为它可能发展为急性骨髓性白血病 (AML)。 MDS 的具体病因尚不清楚，但据信与基因突变、接触某些化学物质和放射疗法有关。

市场概况
预测期 2026-2030
2024 年市场规模 29.5 亿美元
2030 年市场规模 42 亿美元
2025-2030 年复合年增长率 6.02%
成长最快的领域 医院和诊所
最大的市场 北美洲

受多种因素推动，全球骨髓增生异常综合症 (MDS) 治疗市场正在稳步增长。随着全球人口老化，MDS 的发生率预计会上升。这种人口结构的变化导致对 MDS 治疗的需求增加。医疗保健提供者和患者对 MDS 的认识不断提高，从而实现了更早的诊断和干预，进一步促进了市场的成长。由于医疗保健基础设施的改善和先进疗法的普及，发展中经济体正在成为 MDS 治疗市场中越来越重要的参与者。製药公司和政府机构对 MDS 研究和开发持续的投资预计将带来创新的治疗方案并扩大市场。

近年来，全球骨髓增生异常综合症治疗市场取得了显着进步，为患有这种棘手疾病的患者带来了新的希望。标靶治疗、个人化医疗、改进的支持性护理以及正在进行的临床试验正在改变 MDS 治疗的模式。随着人口老化加剧和人们认识的不断提高，MDS 治疗市场将持续扩大，最终为与疾病作斗争的患者带来更好的治疗效果并提高其生活品质。

主要市场驱动因素

呼吸系统疾病盛行率上升推动全球骨髓增生异常综合症 (MDS) 治疗市场发展

主要市场挑战

定价压力

主要市场趋势

技术进步

目录

第 1 章：产品概述

第 2 章：研究方法

第 3 章：执行摘要

第 4 章：顾客之声

第 5 章：全球骨髓增生异常综合症 (MDS) 治疗市场展望

  • 市场规模和预测
    • 按价值
  • 市场占有率和预测
    • 依治疗类型（干细胞移植、免疫治疗、化疗、免疫调节药物、抗贫血药物、其他）
    • 按最终使用者（医院和诊所、门诊护理中心、其他）
    • 按地区
    • 按公司分类（2024）
  • 市场地图

第 6 章：北美骨髓增生异常症候群 (MDS) 治疗市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 北美：国家分析
    • 加拿大
    • 墨西哥

第 7 章：欧洲骨髓增生异常症候群 (MDS) 治疗市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 欧洲：国家分析
    • 英国
    • 义大利
    • 法国
    • 西班牙

第 8 章：亚太地区骨髓增生异常症候群 (MDS) 治疗市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 亚太地区：国家分析
    • 印度
    • 日本
    • 韩国
    • 澳洲

第 9 章：南美洲骨髓增生异常症候群 (MDS) 治疗市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 南美洲：国家分析
    • 阿根廷
    • 哥伦比亚

第 10 章：中东和非洲骨髓增生异常综合症 (MDS) 治疗市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • MEA：国家分析
    • 沙乌地阿拉伯
    • 阿联酋

第 11 章：市场动态

  • 驱动程式
  • 挑战

第 12 章：市场趋势与发展

  • 合併与收购（如有）
  • 产品发布（如果有）
  • 最新动态

第 13 章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的力量
  • 顾客的力量
  • 替代产品的威胁

第 14 章：竞争格局

  • AbbVie Inc.
  • Accord Healthcare Limited
  • Bristol-Myers Squibb Company
  • Jazz Pharmaceuticals Inc.
  • Novartis AG
  • Lupin Limited
  • Otsuka America Pharmaceutical Inc.
  • Takeda Pharmaceutical Company Limited
  • Astex Therapeutics Limited
  • Pfizer Inc.

第 15 章：策略建议

第16章 调査会社について・免责事项

简介目录
Product Code: 19092

Global Myelodysplastic Syndrome (MDS) Treatment Market was valued at USD 2.95 Billion in 2024 and is expected to reach USD 4.20 Billion by 2030 with a CAGR of 6.02% during the forecast period. Myelodysplastic Syndrome (MDS) is a group of blood disorders characterized by dysfunctional blood cell production in the bone marrow. It affects the production of red blood cells, white blood cells, and platelets, leading to a variety of symptoms and complications. Over the years, significant progress has been made in the diagnosis and treatment of MDS, leading to a growing global market for MDS treatment. MDS primarily affects older adults, but it can occur at any age. It is often considered a pre-leukemic condition because it can progress to acute myeloid leukemia (AML). The exact cause of MDS is still unknown, but it is believed to be linked to genetic mutations, exposure to certain chemicals, and radiation therapy.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 2.95 Billion
Market Size 2030USD 4.20 Billion
CAGR 2025-20306.02%
Fastest Growing SegmentHospitals & Clinics
Largest MarketNorth America

The Global Myelodysplastic Syndrome (MDS) Treatment Market is witnessing steady growth, driven by several factors. As the global population continues to age, the incidence of MDS is expected to rise. This demographic shift contributes to an increased demand for MDS treatments. Growing awareness among healthcare providers and patients about MDS has led to earlier diagnosis and intervention, further boosting the market's growth. Developing economies are becoming more significant players in the MDS treatment market due to improvements in healthcare infrastructure and access to advanced therapies. Continued investments in MDS research and development by pharmaceutical companies and government agencies are expected to yield innovative treatment options and expand the market.

The global Myelodysplastic Syndrome treatment market has witnessed remarkable advancements in recent years, offering new hope to patients diagnosed with this challenging condition. Targeted therapies, personalized medicine, improved supportive care, and ongoing clinical trials are transforming the landscape of MDS treatment. With a growing aging population and increasing awareness, the market for MDS treatments is poised for continued expansion, ultimately leading to better outcomes and improved quality of life for patients battling this disease.

Key Market Drivers

Rising Prevalence of Respiratory Diseases is Driving the Global Myelodysplastic Syndrome (MDS) Treatment Market

Respiratory diseases have become a significant global health concern, affecting millions of individuals worldwide. These ailments, which include conditions like asthma, chronic obstructive pulmonary disease (COPD), and bronchitis, can severely impact a person's quality of life and, in some cases, be life-threatening. The rising prevalence of respiratory diseases has led to increased demand for effective treatment options, and one such solution that has gained prominence in recent years is Myelodysplastic Syndrome (MDS) Treatment. Myelodysplastic Syndrome (MDS) Treatment are a form of medication delivery that involves inhaling a nebulized solution through a specialized device. This method is particularly effective for delivering medication directly to the respiratory system, making it a vital component in managing and treating respiratory diseases. The global Myelodysplastic Syndrome (MDS) Treatment market has witnessed significant growth in response to the increasing burden of respiratory diseases. In February 2024, Fortis Healthcare in Mumbai achieved a significant milestone, completing 100 bone marrow transplants, a key treatment for myelodysplastic syndrome, leukemia, and other blood disorders. This accomplishment, along with similar advancements and initiatives, is anticipated to drive growth in the market.

Key Market Challenges

Pricing Pressures

Pricing pressures are a significant challenge in the Myelodysplastic Syndrome (MDS) treatment market as healthcare systems across the globe implement increasingly stringent cost-containment measures. Governments, insurance companies, and payers are placing greater emphasis on cost-effectiveness and value-based healthcare, leading to heightened scrutiny of treatment costs and the value they offer. Pharmaceutical companies are under considerable pressure to demonstrate the clinical and economic value of their products in order to secure reimbursement and negotiate favorable pricing terms. In addition, these companies are tasked with finding ways to lower the overall cost of treatment for patients, including offering more affordable treatment options, exploring alternative delivery methods, or reducing the complexity and duration of therapy. The growing demand for cost-effective solutions is driving the need for innovations that deliver both clinical efficacy and economic viability, compelling drug manufacturers to focus on value-based pricing models that align with payer expectations.

Key Market Trends

Technological Advancements

Technological advancements have consistently played a pivotal role in transforming the landscape of healthcare. One such domain where this transformation is prominently visible is in the treatment of Myelodysplastic Syndrome (MDS), a group of bone marrow disorders that hinder the production of healthy blood cells. The Global Myelodysplastic Syndrome (MDS) Treatment Market is experiencing a significant boost, thanks to the remarkable strides made in technology and research. In March 2020, Gilead Sciences, Inc. and Forty-Seven, Inc. have finalized a deal in which Gilead will purchase Forty-Seven at a price of $95.50 per share in cash. Magrolimab is the primary experimental product being developed by Forty-Seven.

One of the most significant breakthroughs in MDS treatment has been the ability to conduct comprehensive genetic profiling of patients. Advanced genomic sequencing technologies enable doctors to identify specific genetic mutations that drive the development of MDS. This information is crucial in tailoring personalized treatment plans and predicting disease progression accurately. With a better understanding of the genetic basis of MDS, pharmaceutical companies are developing targeted therapies that specifically address the underlying genetic abnormalities. These therapies are more effective and have fewer side effects compared to traditional chemotherapy.

Key Market Players

  • AbbVie Inc.
  • Accord Healthcare Limited
  • Bristol-Myers Squibb Company
  • Jazz Pharmaceuticals Inc.
  • Novartis AG
  • Lupin Limited
  • Otsuka America Pharmaceutical Inc.
  • Takeda Pharmaceutical Company Limited
  • Astex Therapeutics Limited
  • Pfizer Inc.

Report Scope:

In this report, the Global Myelodysplastic Syndrome (MDS) Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Myelodysplastic Syndrome (MDS) Treatment Market, By Treatment Type:

  • Stem Cell Transplant
  • Immune Treatments
  • Chemotherapy
  • Immunomodulatory Drugs
  • Anti-Anaemics
  • Others

Myelodysplastic Syndrome (MDS) Treatment Market, By End User:

  • Hospitals & Clinics
  • Ambulatory Care Centers
  • Others

Myelodysplastic Syndrome (MDS) Treatment Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Myelodysplastic Syndrome (MDS) Treatment Market.

Available Customizations:

Global Myelodysplastic Syndrome (MDS) Treatment market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validations
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Myelodysplastic Syndrome (MDS) Treatment Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Treatment Type (Stem Cell Transplant, Immune Treatments, Chemotherapy, Immunomodulatory Drugs, Anti-anemics, Others)
    • 5.2.2. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2024)
  • 5.3. Market Map

6. North America Myelodysplastic Syndrome (MDS) Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Treatment Type
    • 6.2.2. By End User
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Myelodysplastic Syndrome (MDS) Treatment Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Treatment Type
        • 6.3.1.2.2. By End User
    • 6.3.2. Canada Myelodysplastic Syndrome (MDS) Treatment Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Treatment Type
        • 6.3.2.2.2. By End User
    • 6.3.3. Mexico Myelodysplastic Syndrome (MDS) Treatment Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Treatment Type
        • 6.3.3.2.2. By End User

7. Europe Myelodysplastic Syndrome (MDS) Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Treatment Type
    • 7.2.2. By End User
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Myelodysplastic Syndrome (MDS) Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Treatment Type
        • 7.3.1.2.2. By End User
    • 7.3.2. United Kingdom Myelodysplastic Syndrome (MDS) Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Treatment Type
        • 7.3.2.2.2. By End User
    • 7.3.3. Italy Myelodysplastic Syndrome (MDS) Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Treatment Type
        • 7.3.3.2.2. By End User
    • 7.3.4. France Myelodysplastic Syndrome (MDS) Treatment Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Treatment Type
        • 7.3.4.2.2. By End User
    • 7.3.5. Spain Myelodysplastic Syndrome (MDS) Treatment Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Treatment Type
        • 7.3.5.2.2. By End User

8. Asia-Pacific Myelodysplastic Syndrome (MDS) Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Treatment Type
    • 8.2.2. By End User
    • 8.2.3. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Myelodysplastic Syndrome (MDS) Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Treatment Type
        • 8.3.1.2.2. By End User
    • 8.3.2. India Myelodysplastic Syndrome (MDS) Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Treatment Type
        • 8.3.2.2.2. By End User
    • 8.3.3. Japan Myelodysplastic Syndrome (MDS) Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Treatment Type
        • 8.3.3.2.2. By End User
    • 8.3.4. South Korea Myelodysplastic Syndrome (MDS) Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Treatment Type
        • 8.3.4.2.2. By End User
    • 8.3.5. Australia Myelodysplastic Syndrome (MDS) Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Treatment Type
        • 8.3.5.2.2. By End User

9. South America Myelodysplastic Syndrome (MDS) Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Treatment Type
    • 9.2.2. By End User
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Myelodysplastic Syndrome (MDS) Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Treatment Type
        • 9.3.1.2.2. By End User
    • 9.3.2. Argentina Myelodysplastic Syndrome (MDS) Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Treatment Type
        • 9.3.2.2.2. By End User
    • 9.3.3. Colombia Myelodysplastic Syndrome (MDS) Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Treatment Type
        • 9.3.3.2.2. By End User

10. Middle East and Africa Myelodysplastic Syndrome (MDS) Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Treatment Type
    • 10.2.2. By End User
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Myelodysplastic Syndrome (MDS) Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Treatment Type
        • 10.3.1.2.2. By End User
    • 10.3.2. Saudi Arabia Myelodysplastic Syndrome (MDS) Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Treatment Type
        • 10.3.2.2.2. By End User
    • 10.3.3. UAE Myelodysplastic Syndrome (MDS) Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Treatment Type
        • 10.3.3.2.2. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Porter's Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Products

14. Competitive Landscape

  • 14.1. AbbVie Inc.
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Products & Services
    • 14.1.4. Financials (As Reported)
    • 14.1.5. Recent Developments
    • 14.1.6. Key Personnel Details
    • 14.1.7. SWOT Analysis
  • 14.2. Accord Healthcare Limited
  • 14.3. Bristol-Myers Squibb Company
  • 14.4. Jazz Pharmaceuticals Inc.
  • 14.5. Novartis AG
  • 14.6. Lupin Limited
  • 14.7. Otsuka America Pharmaceutical Inc.
  • 14.8. Takeda Pharmaceutical Company Limited
  • 14.9. Astex Therapeutics Limited
  • 14.10. Pfizer Inc.

15. Strategic Recommendations

16. About Us & Disclaimer